European Commission grants Bristol Myers Squibb approval for Opdivo to treat RCC

Apart from the EU, the Opdivo-Cabometyx combination was approved for the first-line treatment of advanced RCC by the USFDA in January 2021. Credit: National Cancer Institute/Unsplash.